CONMED Corp (New York Stock Exchange:CNMD)
| Market Cap | 1.53B+17.1% |
| Revenue (ttm) | 1.37B+1.7% |
| Net Income | 73.43M+14.6% |
| EPS | 2.42+17.9% |
| Shares Out | 29.80M |
| PE Ratio | 21.28 |
| Forward PE | 10.85 |
| Dividend | n/a |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 331,560 |
| Open | 51.11 |
| Previous Close | 52.83 |
| Day's Range | 51.11 - 52.39 |
| 52-Week Range | 31.44 - 54.80 |
| Beta | 0.91 |
| Analysts | Hold |
| Price Target | 37.50(-27.18%) |
| Earnings Date | Jan 27, 2027 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CNMD
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Analyst consensus
2 firms rating CNMD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Jan 27, 2027Earnings report
Ask Barron about CNMD
$CNMD stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNMD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNMD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNMD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CNMD Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Goods transferred at a point in time | $322.36M | 48.03% |
| General Surgery | $186.72M | 27.82% |
| Orthopedic Surgery | $148.83M | 22.18% |
| Services transferred over time | $13.20M | 1.97% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CNMD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNMD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CNMD
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $95.96M |
| VTIVanguard Morningstar Total Stock Market ETF | $44.29M |
| IWMiShares Russell 2000 ETF | $43.02M |
| VBVanguard Morningstar Small-Cap ETF | $31.18M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $29.34M |
| VBRVanguard Morningstar Small-Cap Value ETF | $20.29M |
Estimated from each fund’s disclosed top holdings × AUM
CNMD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CNMD’s recent data — informational, not investment advice
What’s Behind the Score
News check: CNMD headlines lack concrete catalysts; Q2 recap is benchmarking-focused and earnings announcement is procedural with no guidance hint.
